For the committee, some of the reasons it used to reject adding Pompe disease to Australia’s newborn bloodspot screening programs are perversely the same as those it invoked to support the addition of Hurler (MPS I) and Hunter (MPS II) syndromes.
Decision-making at its nadir, exposing the cruelty of incoherence
September 16, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech -
Cartherics secures Japanese patent to bolster cell therapy push
June 10, 2026 - - Australian Biotech -
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News

